An alphavirus-based therapeutic cancer vaccine: from design to clinical trial
Publication year
2019Source
Cancer Immunology Immunotherapy, 68, 5, (2019), pp. 849-859ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Radiation Oncology
Journal title
Cancer Immunology Immunotherapy
Volume
vol. 68
Issue
iss. 5
Page start
p. 849
Page end
p. 859
Subject
Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Cancer immunotherapy has greatly advanced in recent years. Most immunotherapeutic strategies are based on the use of immune checkpoint blockade to unleash antitumor immune responses or on the induction or adoptive transfer of immune effector cells. We aim to develop therapeutic vaccines based on recombinant Semliki Forest virus vectors to induce tumor-specific effector immune cells. In this review, we describe our ongoing work on SFV-based vaccines targeted against human papillomavirus- and hepatitis C virus-related infections and malignancies, focusing on design, delivery, combination strategies, preclinical efficacy and product development for a first-in-man clinical trial with an HPV-specific vaccine.
This item appears in the following Collection(s)
- Academic publications [227437]
- Electronic publications [107154]
- Faculty of Medical Sciences [86157]
- Open Access publications [76296]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.